ICH Urged to Allow for Bioaccessibility in Metal Impurities Standards
This article was originally published in The Gold Sheet
Executive Summary
The world’s leading drug regulatory authorities aim to agree in a June ICH meeting on final standards for elemental impurities like arsenic, lead, cadmium and mercury. Industry has some ideas on what they should decide.
You may also be interested in...
ICH and USP Agree to Harmonize Metal Impurity Limits
ICH and USP have announced plans to harmonize their limits in pharmaceuticals for elemental impurities like arsenic, lead, cadmium and mercury. An ICH Q3D Step 4 guideline that sets these limits is imminent.
Restraint Advised in Testing for Elemental Impurities
Experts explain how to prepare for new metal impurities limits expected in June.
As ICH Q3D Metal Impurity Limits Near, Industry Worries What New Tests May Find
With ICH planning to propose Q3D metal impurity limits in June and USP requiring new metals test methods soon thereafter, pharmaceutical companies are wondering whether any of their ingredients might fail the tests, perhaps requiring them to reformulate products or suspend production. Early indications from FDA and industry testing are largely reassuring, while highlighting some areas for further inquiry.